leadf
logo-loader
viewHumanigen, Inc.

Humanigen plans 1:5 reverse stock split ahead of potential uplisting to Nasdaq exchange

The split is expected to occur at 4:30pm EST on September 11 this year, with trading expected to begin on the split-adjusted basis on the OTCQB venture market at the market open on September 14

Humanigen, Inc. -
The stock will continue to trade under the symbol 'HGEN' but the security will be assigned a new CUSIP number

Humanigen Inc (OTCMKTS:HGEN), the biotech firm focused on cancers and infectious diseases, is poised to carry out a reverse share split ahead of a potential listing on the Nasdaq exchange.

In a statement, the firm said its board had decided to carry out a 1:5 (every five shares consolidated into one) reverse split of its outstanding shares, reducing the number of shares to around 42 million from 211 million previously.

READ: Humanigen says lenzilumab demonstrated 80% reduction in relative risk of invasive mechanical ventilation and/or death in coronavirus patients

The split is expected to occur at 4:30pm EST on September 11 this year, with trading expected to begin on the split-adjusted basis on the OTCQB venture market at the market open on September 14.

The stock will continue to trade under the symbol 'HGEN' but the security will be assigned a new CUSIP number, the group told investors.

The move is "intended to enable the company to achieve several important corporate objectives", the company said, including satisfying the minimum bid price requirement in connection with the company's application to list on the Nasdaq and making additional shares of common stock available for future issue.

Last week, the company revealed that the first case-control data of lenzilumab in severe coronavirus (COVID-19) cases showed an 80% reduction in relative risk of invasive mechanical ventilation (IMV) and/or death for patients treated with the drug compared to a matched control group.

Lenzilumab, an anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody drug candidate, is being evaluated in an ongoing Phase III trial and was selected by the National Institutes of Health for its COVID-19 Big Effect Trial.

Contact the author at giles@proactiveinvestors.com

Quick facts: Humanigen, Inc.

Price: - -

OTCMKTS:HGEN
Market: OTCQB
Market Cap: -
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Humanigen, Inc. named herein, including the promotion by the Company of Humanigen, Inc. in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Humanigen announces 71.8 million dollars in financing

Humanigen (OTCQB: HGEN) Chairman and CEO Cameron Durant joined Steve Darling from Proactive Vancouver with news the company has secured almost 72 million dollars in financing. Durant discusses those making up that financing which is a big part of the story..

on 3/6/20

2 min read